Cereblon Modulator Analogs for Undruggable Oncoprotein Degradation

The patent uses cereblon as an intermediary E3 ubiquitin ligase to target undruggable oncoproteins. The disclosed compounds bind to cereblon and induce ubiquitination of target oncoproteins, enabling indirect targeting of proteins that cannot be directly bound by conventional drugs. This mediator approach allows targeting of transcription factors and chimeric fusion oncoproteins that were previously considered undruggable.

The patent employs protein degradation as a different mechanism parameter change from traditional inhibition. Instead of blocking protein function through binding, the compounds induce proteasomal degradation of target oncoproteins by recruiting them to the cereblon E3 ligase complex, fundamentally changing the therapeutic parameter from functional inhibition to complete protein removal.

The disclosed compounds exhibit local quality optimization through specific structural features that enhance binding to cereblon. The molecular structures contain specific functional groups and spatial arrangements that provide selective interaction with the cereblon binding pocket, achieving both potency and selectivity for the intended target while minimizing off-target effects.

The patent employs structure-based design where compounds are developed as analogs and derivatives of initial cereblon-binding scaffolds. By copying and optimizing the core binding pharmacophore with various substituents, the research identifies compounds with enhanced potency and selectivity, systematically improving the therapeutic agent quality.